Oxcarbazepine is an anticonvulsant agent generally used in the treatment of partial seizures in children and adults with epilepsy. It is a structural derivative of carbamazepine, with an extra oxygen atom to the benzylcarboxamide group. The presence of an extra oxygen atom in the structure reduces the susceptibility of the drug to hepatic metabolism, leading to prolonged pharmacological action or half life of the drug. In addition, the structural modification reduces the drug's potential to cause serious anemias often seen with carbamazepine. The mechanism of action of oxcarbazepine is similar to that of carbamazepine, which involves the inhibition of voltage-gated sodium channels.

Structure

Similar Structures

Synonyms

10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide
OCBZ
Oxcarbamazepine
Oxcarbazepina
Oxcarbazepine
Oxcarbazepinum

External IDs

GP 47680 / GP-47680 / KIN-493 / SPN-804

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Oxcarbazepine	Tablet	600 mg	Oral	Jubilant Generics Limited	Not applicable	Not applicable
Oxcarbazepine	Tablet	300 mg	Oral	Jubilant Generics Limited	Not applicable	Not applicable
Oxcarbazepine	Tablet	150 mg	Oral	Jubilant Generics Limited	Not applicable	Not applicable
Oxtellar XR	Tablet	600 mg/1	Oral	Supernus Pharmaceuticals, Inc.	2013-01-17	Not applicable
Oxtellar XR	Tablet	300 mg/1	Oral	Supernus Pharmaceuticals, Inc.	2013-01-17	Not applicable
Oxtellar XR	Tablet	150 mg/1	Oral	Supernus Pharmaceuticals, Inc.	2013-01-17	Not applicable
Trileptal	Tablet, film coated	150 mg/1	Oral	Novartis Pharmaceuticals Corporation	2006-05-10	2006-05-10
Trileptal	Tablet, film coated	300 mg/1	Oral	Novartis Pharmaceuticals Corporation	2000-01-30	Not applicable
Trileptal	Tablet, film coated	300 mg/1	Oral	Remedy Repack	2018-08-07	Not applicable
Trileptal	Tablet, film coated	150 mg/1	Oral	Novartis Pharmaceuticals Corporation	2000-01-30	Not applicable

Additional Data Available

Application Number

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Apo-oxcarbazepine	Tablet	600 mg	Oral	Apotex Corporation	2006-08-01	Not applicable
Apo-oxcarbazepine	Tablet	300 mg	Oral	Apotex Corporation	2006-08-01	Not applicable
Apo-oxcarbazepine	Tablet	150 mg	Oral	Apotex Corporation	2006-08-01	Not applicable
Jamp-oxcarbazepine	Tablet	150 mg	Oral	Jamp Pharma Corporation	2015-06-08	Not applicable
Jamp-oxcarbazepine	Tablet	600 mg	Oral	Jamp Pharma Corporation	2015-06-08	Not applicable
Jamp-oxcarbazepine	Tablet	300 mg	Oral	Jamp Pharma Corporation	2015-06-08	Not applicable
Novo-oxcarbazepine	Tablet	600 mg	Oral	Novopharm Limited	Not applicable	Not applicable
Novo-oxcarbazepine	Tablet	300 mg	Oral	Novopharm Limited	Not applicable	Not applicable
Novo-oxcarbazepine	Tablet	150 mg	Oral	Novopharm Limited	Not applicable	Not applicable
Oxcarbazepine	Tablet, film coated	300 mg/1	Oral	Physicians Total Care, Inc.	2009-10-16	Not applicable

Additional Data Available

Application Number

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

International/Other Brands

Actinium / Barzepin / Carbox / Deprectal / Lonazet / Oxalepsy / Oxetol / Oxpin / Oxrate / Oxypine / Pharozepine / Prolepsi / Timox / Trexapin / Trileptin

Categories

UNII

VZI5B1W380

CAS number

28721-07-5

Weight

Average: 252.268
Monoisotopic: 252.089877638

Chemical Formula

C₁₅H₁₂N₂O₂

InChI Key

CTRLABGOLIVAIY-UHFFFAOYSA-N

InChI

InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)

IUPAC Name

9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide

SMILES

NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2

Pharmacology

Indication

For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.

Associated Conditions

Pharmacodynamics

Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsies. It works by decreasing abnormal electrical activity in the brain.

Mechanism of action

The exact mechanism by which oxcarbazepine exerts its anticonvulsant effect is unknown. It is known that the pharmacological activity of oxcarbazepine occurs primarily through its 10-monohydroxy metabolite (MHD). In vitro studies indicate an MHD-induced blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neuronal membranes, inhibition of repetitive neuronal discharges, and diminution of propagation of synaptic impulses.

Target	Actions	Organism
ASodium channel protein type 5 subunit alpha	inhibitor	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of oxcarbazepine. After single-dose administration of Trileptal tablets to healthy male volunteers under fasted conditions, the median tmax was 4.5 (range 3 to 13) hours. After single-dose administration of Trileptal oral suspension to healthy male volunteers under fasted conditions, the median tmax was six hours. Steady-state plasma concentrations of MHD are reached within 2-3 days in patients when Trileptal is given twice a day.

Volume of distribution

49 L

Protein binding

Approximately 40% of the active 10-monohydroxy metabolite (MHD) is bound to serum proteins, predominantly to albumin. Neither oxcarbazepine nor its MHD binds with alpha-1-acid glycoprotein.

Metabolism

Oxcarbazepine is completely absorbed and extensively metabolized to its pharmacologically active 10-monohydroxy metabolite (MHD) by cytosolic enzymes. MHD is metabolized further by conjugation with glucuronic acid.

Route of elimination

Oxcarbazepine is cleared from the body mostly in the form of metabolites which are predominantly excreted by the kidneys. Fecal excretion accounts for less than 4% of the administered dose.

Half life

The half-life of the parent is about 2 hours, while the half-life of MHD is about 9 hours, so that MHD is responsible for most anti-epileptic activity.

Clearance

Not Available

Toxicity

Isolated cases of overdose with oxcarbazepine have been reported. The maximum dose taken was approximately 24,000 mg. All patients recovered with symptomatic treatment.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Carbamazepine Metabolism Pathway	Drug metabolism

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
HLA class I histocompatibility antigen, B-15 alpha chain	HLA-B*15:02	Not Available	HLA-B*15	ADR Directly Studied	Patients who carry this allele may be at an increased risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis when treated with oxcarbazepine.	Details

Interactions

Drug Interactions

Drug	Interaction
Unlock Additional Data
(R)-warfarin	The metabolism of (R)-warfarin can be increased when combined with Oxcarbazepine.
(S)-Warfarin	The metabolism of (S)-Warfarin can be increased when combined with Oxcarbazepine.
2,5-Dimethoxy-4-ethylthioamphetamine	The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine	Oxcarbazepine may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
4-Bromo-2,5-dimethoxyamphetamine	The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin	The metabolism of 4-hydroxycoumarin can be increased when combined with Oxcarbazepine.
4-Methoxyamphetamine	The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine	The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine	Oxcarbazepine may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-Deazaguanine	Oxcarbazepine may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Judith Aronhime, "New crystal forms of oxcarbazepine and processes for their preparation." U.S. Patent US20030004154, issued January 02, 2003.

US20030004154

General References

Mazza M, Della Marca G, Di Nicola M, Martinotti G, Pozzi G, Janiri L, Bria P, Mazza S: Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007 May;10(3):397-401. Epub 2007 Feb 14. [PubMed:17300991]

External Links

Human Metabolome Database: HMDB0014914
KEGG Drug: D00533
KEGG Compound: C07492
PubChem Compound: 34312
PubChem Substance: 46507580
ChemSpider: 31608
BindingDB: 34179
ChEBI: 7824
ChEMBL: CHEMBL1068
Therapeutic Targets Database: DAP000528
PharmGKB: PA450732
Wikipedia: Oxcarbazepine

ATC Codes

N03AF02 — Oxcarbazepine

AHFS Codes

28:12.92 — Miscellaneous Anticonvulsants

FDA label

Download (195 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	2
1	Completed	Basic Science	Epilepsies	1
1	Completed	Treatment	Epilepsies	2
1	Completed	Treatment	Epilepsies / Epilepsy, Localization Related	1
1	Completed	Treatment	Epilepsy, Localization Related	1
1	Completed	Treatment	Seizures	2
1	Terminated	Supportive Care	Malignancies	1
2	Completed	Treatment	Disseminated Sclerosis	1
2, 3	Active Not Recruiting	Treatment	Partial onset seizure Epilepsy	1
2, 3	Completed	Treatment	Schizophrenic Disorders	1
3	Active Not Recruiting	Treatment	Adverse Effects / Epilepsy, Localization Related	1
3	Completed	Treatment	Agitation Aggression in Dementia	1
3	Completed	Treatment	Epilepsies	2
3	Completed	Treatment	Epilepsies / Epilepsy, Localization Related	1
3	Completed	Treatment	Epilepsy, Localization Related	2
3	Not Yet Recruiting	Treatment	Pediatric Chronic Neuropathic Pain	1
3	Terminated	Treatment	Anxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders	1
3	Terminated	Treatment	Epilepsy, Localization Related	1
4	Completed	Treatment	Bipolar Disorder (BD)	2
4	Completed	Treatment	Bronchial Asthma	1
4	Completed	Treatment	Epilepsies	1
4	Completed	Treatment	Epilepsy, Partial Seizures	2
4	Completed	Treatment	Oppositional Defiant Disorder	1
4	Completed	Treatment	Peripheral Nerve Injury (PNI) / Polyneuropathies / Postherpetic Neuralgia	1
4	Completed	Treatment	Seizures, Focal	1
4	Completed	Treatment	Neurocostal neuralgia / Spinal Cord Injuries (SCI)	1
4	Not Yet Recruiting	Treatment	Epilepsy, Localization Related	1
4	Not Yet Recruiting	Treatment	Trigeminal Neuralgia (TN)	1
4	Recruiting	Treatment	Bipolar Disorder (BD)	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Treatment	Autism, Early Infantile	1
Not Available	Completed	Treatment	Epilepsies / Seizures	3
Not Available	Enrolling by Invitation	Not Available	Bipolar Disorder (BD)	1
Not Available	Recruiting	Not Available	Epilepsies	1

Pharmacoeconomics

Manufacturers

Ranbaxy laboratories ltd
Novartis pharmaceuticals corp
Apotex inc
Breckenridge pharmaceutical inc
Cadista pharmaceuticals inc
Glenmark generics ltd
Roxane laboratories inc
Sun pharmaceutical industries ltd
Taro pharmaceutical industries ltd
Teva pharmaceuticals usa

Packagers

Amerisource Health Services Corp.
Apotex Inc.
Ascend Laboratories LLC
Atlantic Biologicals Corporation
Breckenridge Pharmaceuticals
Bryant Ranch Prepack
Cardinal Health
Glenmark Generics Ltd.
Innoviant Pharmacy Inc.
Murfreesboro Pharmaceutical Nursing Supply
Nexgen Pharma Inc.
Novartis AG
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Ranbaxy Laboratories
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Roxane Labs
Sandoz
Southwood Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Taro Pharmaceuticals USA
Teva Pharmaceutical Industries Ltd.
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Suspension	Oral	300 mg/5mL
Suspension	Oral	60 mg/1mL
Tablet	Oral	150 mg/1
Tablet	Oral	300 mg/1
Tablet	Oral	600 mg/1
Tablet, film coated	Oral	150 mg/1
Tablet, film coated	Oral	300 mg/1
Tablet, film coated	Oral	600 mg/1
Tablet	Oral	150 mg
Tablet	Oral	300 mg
Tablet	Oral	600 mg
Suspension	Oral	60 mg

Prices

Unit description	Cost	Unit
OXcarbazepine 300 mg/5ml Suspension 250ml Bottle	162.03USD	bottle
Trileptal 600 mg tablet	7.05USD	tablet
Oxcarbazepine 600 mg tablet	5.06USD	tablet
Trileptal 300 mg tablet	3.84USD	tablet
Oxcarbazepine 300 mg tablet	2.75USD	tablet
Trileptal 150 mg tablet	2.1USD	tablet
Oxcarbazepine 150 mg tablet	1.53USD	tablet
Trileptal 300 mg/5ml Suspension	0.79USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
Unlock Additional Data
CA2277791	No	2008-11-18	2018-02-12
US7037525	Yes	2006-05-02	2018-08-12
US8119148	Yes	2012-02-21	2021-06-19
US7910131	No	2011-03-22	2027-04-13
US9119791	No	2015-09-01	2027-04-13
US8821930	No	2014-09-02	2027-04-13
US8617600	No	2013-12-31	2027-04-13
US7722898	No	2010-05-25	2027-04-13
US9370525	No	2016-06-21	2027-04-13
US9351975	No	2016-05-31	2027-04-13
US9855278	No	2018-01-02	2027-04-13
US10220042	No	2007-04-13	2027-04-13

Additional Data Available

Filed On

The date on which a patent was filed with the relevant government.

Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	215.5 °C	PhysProp
water solubility	308 mg/L at 25 °C (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))	Not Available
logP	1.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.16 mg/mL	ALOGPS
logP	1.76	ALOGPS
logP	1.82	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Acidic)	13.18	ChemAxon
pKa (Strongest Basic)	-4.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	63.4 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	71.56 m³·mol^-1	ChemAxon
Polarizability	25.72 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9894
Blood Brain Barrier	+	0.9975
Caco-2 permeable	+	0.6299
P-glycoprotein substrate	Non-substrate	0.7157
P-glycoprotein inhibitor I	Non-inhibitor	0.7193
P-glycoprotein inhibitor II	Non-inhibitor	0.9348
Renal organic cation transporter	Non-inhibitor	0.8176
CYP450 2C9 substrate	Non-substrate	0.773
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.6022
CYP450 1A2 substrate	Non-inhibitor	0.7266
CYP450 2C9 inhibitor	Non-inhibitor	0.7371
CYP450 2D6 inhibitor	Non-inhibitor	0.9329
CYP450 2C19 inhibitor	Non-inhibitor	0.7428
CYP450 3A4 inhibitor	Non-inhibitor	0.8819
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8034
Ames test	Non AMES toxic	0.5078
Carcinogenicity	Non-carcinogens	0.9118
Biodegradation	Not ready biodegradable	0.8977
Rat acute toxicity	1.9871 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9327
hERG inhibition (predictor II)	Non-inhibitor	0.869

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0pb9-0090000000-46d01e1171f998679d03
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0f8i-1790000000-cd62672e7fa7c39f0be1
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0kar-0690000000-cbc95a31913165d691a7
MS/MS Spectrum - , positive	LC-MS/MS	splash10-001i-2910000000-d1242af6b8148ffac3a9

Taxonomy

Description: This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Benzazepines
Sub Class: Dibenzazepines
Direct Parent: Dibenzazepines
Alternative Parents: Aryl alkyl ketones / Azepines / Benzenoids / Vinylogous amides / Isoureas / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Imines / Hydrocarbon derivatives
Substituents: Dibenzazepine / Aryl ketone / Aryl alkyl ketone / Azepine / Benzenoid / Vinylogous amide / Isourea / Ketone / Carboximidic acid derivative / Azacycle
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: cyclic ketone, dibenzoazepine (CHEBI:7824)

Targets

Details1. Sodium channel protein type 5 subunit alpha

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function: This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name: SCN5A
Uniprot ID: Q14524
Uniprot Name: Sodium channel protein type 5 subunit alpha
Molecular Weight: 226937.475 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK: Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc). 2010 Apr;46(4):265-77. doi: 10.1358/dot.2010.46.4.1445795. [PubMed:20502724]

Enzymes

Details1. Cytochrome P450 2C19

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Lakehal F, Wurden CJ, Kalhorn TF, Levy RH: Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res. 2002 Dec;52(2):79-83. [PubMed:12458024]
Turnheim K: [Drug interactions with antiepileptic agents]. Wien Klin Wochenschr. 2004 Feb 28;116(4):112-8. [PubMed:15038401]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Bang L, Goa K: Oxcarbazepine: a review of its use in children with epilepsy. Paediatr Drugs. 2003;5(8):557-73. [PubMed:12895138]
Andreasen AH, Brosen K, Damkier P: A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007 Mar;48(3):490-6. doi: 10.1111/j.1528-1167.2007.00924.x. [PubMed:17346248]
Turnheim K: [Drug interactions with antiepileptic agents]. Wien Klin Wochenschr. 2004 Feb 28;116(4):112-8. [PubMed:15038401]

Details3. Cytochrome P450 3A5

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Inducer

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Bang L, Goa K: Oxcarbazepine: a review of its use in children with epilepsy. Paediatr Drugs. 2003;5(8):557-73. [PubMed:12895138]

Details4. UDP-glucuronosyltransferase 1-1

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate
Inducer

General Function: Steroid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name: UGT1A1
Uniprot ID: P22309
Uniprot Name: UDP-glucuronosyltransferase 1-1
Molecular Weight: 59590.91 Da

References

Interactions [Link]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Inducer

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Scott LJ: Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs. 2018 Feb;78(2):245-256. doi: 10.1007/s40265-018-0864-z. [PubMed:29380288]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2019 13:09

Oxcarbazepine

Identification

Structure for Oxcarbazepine (DB00776)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

References

References

References

Carriers

Transporters

References